98%
921
2 minutes
20
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs). Rat peritoneal macrophages were isolated, cultured, and exposed to either human or rat RBCs. Human RBCs were identified using CD235a, while rat RBCs were pre-labeled with DeepRed. Flow cytometry analysis was conducted using CD163 to identify macrophages and propidium iodine (PI) exclusion to gate living cells. The results showed a substantial difference in phagocytic activity: 5.08% of macrophages engulfed human RBCs, while only 1.59% phagocytosed rat RBCs, yielding a relative phagocytosis index of 3.21. This protocol allows for quantitative assessment of immune compatibility and offers a reproducible method to evaluate innate immune responses in xenotransplantation. It holds potential for refining donor-recipient selection and guiding immunosuppressive strategies in translational research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3791/68904 | DOI Listing |
J Vis Exp
August 2025
Institute of Regenerative Medicine, and Department of Dermatology, Affiliated Hospital of Jiangsu University, Jiangsu University; Haihe Laboratory of Cell Ecosystem, Institute of Hematology, Chinese Academy of Medical Sciences; Guangdong Provincial Key Laboratory of Large Animal Models for Biomedici
Xenogeneic cell transplantation often faces significant immune rejection, even in immunodeficient animal models. Among residual immune components, macrophages can actively phagocytose transplanted human cells, posing a challenge to long-term engraftment. To address this, we developed a standardized in vitro assay to quantify macrophage-mediated phagocytosis of human versus rat red blood cells (RBCs).
View Article and Find Full Text PDFInt J Pharm X
December 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwada, Punjab, India.
The study explored HSPiP and QbD-(quality by design) enabled optimized cubosomes for sustained drug release, improved permeation, and enhanced oral bioavailability. OCUB1 (the optimized product) was characterized for size, zeta potential (ZP), thermal analysis, and surface roughness. drug release and hemolysis studies were carried out using a dialysis membrane and rat erythrocytes (4 % suspension), respectively.
View Article and Find Full Text PDFBiology (Basel)
August 2025
Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand.
Anemia remains a widespread public health concern, and the search for interventions demonstrating potent anti-anemic activity is critical for reducing its impact among high-risk populations. Conventional iron therapies are associated with several complications and potential adverse effects. This study explored a polyherbal approach to develop a safer and more effective alternative treatment for anemia.
View Article and Find Full Text PDFEnviron Int
August 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. Electronic address:
Bisphenols, frequently used in the plastics industry, have been recognized as environmental pollutants. Bans on bisphenol A use led to the replacement by alternatives. There are, however, almost no data on their biological effects in humans.
View Article and Find Full Text PDFACS Med Chem Lett
August 2025
Pfizer Inc, South San Francisco, California 94080, United States.
This report details the discovery path of GBT021601 (osivelotor) (), a novel, small molecule, sickle hemoglobin (HbS) polymerization inhibitor. Following a streamlined testing funnel with cassette dosing in rat pharmacokinetic (PK) studies, we identified this next-generation HbS polymerization inhibitor, which had improved PK properties compared with the first-in-class drug, voxelotor (). GBT021601 has ∼4.
View Article and Find Full Text PDF